Research programme: DYRK1A inhibitors - Biosplice Therapeutics
Alternative Names: Dual specificity tyrosine phosphorylation-regulated kinase 1A inhibitors - Biosplice TherapeuticsLatest Information Update: 01 Sep 2023
At a glance
- Originator Biosplice Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 01 Sep 2023 Pharmacodynamics data from preclinical trials in Haematological malignancies and Solid tumours released by Biosplice Therapeutics, prior to September 2023
- 31 Aug 2023 Preclinical trials in Haematological malignancies in USA (PO), prior to August 2023 (Biosplice Therapeutics pipeline, August 2023)
- 31 Aug 2023 Preclinical trials in Solid tumours in USA (PO), prior to August 2023 (Biosplice Therapeutics pipeline, August 2023)